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BACKGROUND
The safety, efficacy, and appropriate timing of isoniazid therapy to prevent tuberculosis 
in pregnant women with human immunodeficiency virus (HIV) infection who are receiv-
ing antiretroviral therapy are unknown.
METHODS
In this multicenter, double-blind, placebo-controlled, noninferiority trial, we randomly 
assigned pregnant women with HIV infection to receive isoniazid preventive therapy for 
28 weeks, initiated either during pregnancy (immediate group) or at week 12 after de-
livery (deferred group). Mothers and infants were followed through week 48 after deliv-
ery. The primary outcome was a composite of treatment-related maternal adverse events 
of grade 3 or higher or permanent discontinuation of the trial regimen because of toxic 
effects. The noninferiority margin was an upper boundary of the 95% confidence inter-
val for the between-group difference in the rate of the primary outcome of less than 
5 events per 100 person-years.
RESULTS
A total of 956 women were enrolled. A primary outcome event occurred in 72 of 477 
women (15.1%) in the immediate group and in 73 of 479 (15.2%) in the deferred group 
(incidence rate, 15.03 and 14.93 events per 100 person-years, respectively; rate difference, 
0.10; 95% confidence interval [CI], −4.77 to 4.98, which met the criterion for noninferi-
ority). Two women in the immediate group and 4 women in the deferred group died 
(incidence rate, 0.40 and 0.78 per 100 person-years, respectively; rate difference, −0.39; 
95% CI, −1.33 to 0.56); all deaths occurred during the postpartum period, and 4 were 
from liver failure (2 of the women who died from liver failure had received isoniazid 
[1 in each group]). Tuberculosis developed in 6 women (3 in each group); the incidence 
rate was 0.60 per 100 person-years in the immediate group and 0.59 per 100 person-
years in the deferred group (rate difference, 0.01; 95% CI, −0.94 to 0.96). There was a 
higher incidence in the immediate group than in the deferred group of an event in-
cluded in the composite adverse pregnancy outcome (stillbirth or spontaneous abortion, 
low birth weight in an infant, preterm delivery, or congenital anomalies in an infant) 
(23.6% vs. 17.0%; difference, 6.7 percentage points; 95% CI, 0.8 to 11.9).
CONCLUSIONS
The risks associated with initiation of isoniazid preventive therapy during pregnancy 
appeared to be greater than those associated with initiation of therapy during the 
postpartum period. (Funded by the National Institutes of Health; IMPAACT P1078 TB 
APPRISE ClinicalTrials.gov number, NCT01494038.)
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Tuberculosis is the leading cause of health complications and death among persons with human immunodeficiency 
virus (HIV) infection who reside in low-income 
and middle-income countries with a high tuber-
culosis burden.1 Among women, tuberculosis 
predominantly affects those of reproductive age. 
When tuberculosis develops during pregnancy 
or the early postpartum period, it is associated 
with adverse maternal, pregnancy, and infant 
outcomes.2-7 There is consensus regarding the 
net benefit of treating active tuberculosis during 
pregnancy and providing isoniazid to prevent 
active tuberculosis in persons with HIV, particu-
larly in persons who have latent tuberculosis 
infection. However, safety and efficacy data are 
lacking regarding isoniazid preventive therapy in 
pregnant women who are receiving antiretro-
viral therapy (ART), because pregnant women 
have been consistently excluded from trials of 
isoniazid preventive therapy.8-14
Many physiological changes that occur dur-
ing pregnancy and the postpartum period af-
fect the immune system and the way drugs are 
absorbed, distributed, metabolized, and elimi-
nated.15-17 Data from small, retrospective stud-
ies18,19 suggest that women who are pregnant or 
who have given birth in the previous 3 months 
have a higher risk of adverse events and drug-
induced liver injury, including from isoniazid, 
than women who are not pregnant or who have 
not recently given birth.16,20 World Health Orga-
nization (WHO) guidelines recommend initia-
tion of isoniazid preventive therapy in pregnant 
women with HIV on the basis of data from 
nonpregnant adults.14 The primary objective of 
the International Maternal Pediatric Adolescent 
AIDS Clinical Trials (IMPAACT) Network P1078 
TB APPRISE trial (TB Ante vs. Postpartum Pre-
vention with INH in HIV Seropositive Mothers 
and Their Exposed Infants) was to evaluate the 
safety of initiating isoniazid preventive therapy 
during pregnancy, as compared with initiating 
it during the postpartum period, in women with 
HIV who are living in areas with a high tuber-
culosis burden. We hypothesized that initiating 
isoniazid preventive therapy during pregnancy 
would be as safe as deferring therapy to week 
12 after delivery.
Me thods
Trial Design and Treatment
We conducted a prospective, double-blind, placebo-
controlled, randomized, noninferiority trial at 
13 sites in eight countries that have a high 
prevalence of tuberculosis (≥60 cases per 100,000 
population). Participants were randomly assigned 
to begin taking oral isoniazid either during preg-
nancy (immediate group) or at week 12 after 
delivery (deferred group). The immediate group 
received isoniazid (300 mg daily) from the time 
of trial entry through 28 weeks after enrollment 
and then received placebo until week 40 after 
delivery. The deferred group received placebo 
from the time of trial entry until week 12 after 
delivery and then received isoniazid (300 mg 
daily) for 28 weeks. All women received locally 
supplied, open-label pyridoxine (vitamin B6) and 
a prenatal multivitamin from the time of trial 
entry until week 40 after delivery. Randomiza-
tion was stratified according to the duration of 
gestation at trial entry (≥14 weeks to <24 weeks 
or ≥24 weeks to ≤34 weeks) and was balanced at 
each site. Full details of the trial design and 
conduct are provided in the protocol and the 
statistical analysis plan, available with the full 
text of this article at NEJM.org.
Participants
Eligible participants were pregnant women, at 14 
weeks through 34 weeks of gestation, who had 
HIV infection and were 18 years of age or older, 
weighed at least 35 kg, and had an absolute neu-
trophil count of 750 cells or more per cubic milli-
meter, a hemoglobin level of 7.5 g or more per 
deciliter, a platelet count of 50,000 or more per 
cubic millimeter, and levels of aspartate amino-
transferase (AST), alanine aminotransferase (ALT), 
and total bilirubin that were no more than 1.25 
times the upper limit of the normal range with-
in 30 days before trial entry. Exclusion criteria 
were suspected active tuberculosis, recent known 
tuberculosis exposure, treatment for tuberculo-
sis for more than 30 days in the previous year, 
evidence of recent acute hepatitis, or peripheral 
neuropathy of grade 1 or higher. Evidence of 
latent tuberculosis infection was not required for 
entry.
The New England Journal of Medicine 
Downloaded from nejm.org at STELLENBOSCH UNIVERSITY on October 18, 2021. For personal use only. No other uses without permission. 
 Copyright © 2019 Massachusetts Medical Society. All rights reserved. 
n engl j med 381;14 nejm.org October 3, 2019 1335
Isoniazid in HIV-Infected Pregnant Women
Trial Oversight
All women provided written informed consent. 
The trial was approved by local and collaborat-
ing institutional review boards and was reviewed 
every 6 months by an independent data and 
safety monitoring board (see the Supplementary 
Appendix, available at NEJM.org). The isoniazid 
and placebo were supplied by the Clinical Re-
search Products Management Center of the Na-
tional Institute of Allergy and Infectious Dis-
eases. The isoniazid, placebo, and testing kits 
were purchased with trial funds; there was no 
commercial support for the trial. In February 
2016, in response to a request by the data and 
safety monitoring board, a letter about potential 
risks of receiving isoniazid preventive therapy in 
addition to ART was issued to all participants 
after two participants in the trial died from ful-
minant liver failure.
The data were gathered at the local sites; the 
IMPAACT Statistical and Data Analysis Center 
analyzed the data according to the statistical 
analysis plans. All the authors vouch for the ac-
curacy and completeness of the data and analyses 
and for the fidelity of the trial to the protocol.
Trial Procedures
Baseline serologic testing for HIV antibodies, an 
assessment of CD4 count, an HIV type 1 quanti-
tative RNA assay, testing for hepatitis C virus 
antibody and hepatitis B surface antigen, an as-
sessment of creatinine and glucose levels, and an 
interferon gamma release assay (IGRA) for tuber-
culosis (with the use of the QuantiFERON-TB 
Gold test21) were performed at entry. Follow-up 
visits occurred every 4 weeks during pregnancy 
and at labor and delivery; follow-up of mothers 
and infants occurred every 4 weeks after delivery 
for 48 weeks. Assessments included a medical 
history, physical examination, complete blood 
count, measurement of the ALT level (AST and 
total bilirubin levels were also assessed if there 
was an elevation in ALT level of grade 1 or high-
er), assessment of tuberculosis exposure or dis-
ease (with acid-fast bacilli smear and Mycobacte-
rium tuberculosis culture performed if tuberculosis 
was suspected), maternal peripheral neuropathy 
screening,22 and HIV testing of the infant. Adher-
ence to the trial regimen was assessed monthly 
on the basis of patient-reported adherence and 
pill counts.
Primary Outcome
The primary outcome was a composite safety 
outcome of maternal adverse events of grade 3 or 
higher that were possibly, probably, or definitely 
related to isoniazid or placebo or permanent 
discontinuation of the trial regimen because of 
toxic effects, whichever occurred first, through 
week 48 after delivery. Members of an indepen-
dent end-point review committee, who were un-
aware of the trial-group assignments, determined 
whether adverse events were related to isoniazid 
or placebo. Hepatotoxicity and peripheral neu-
ropathy were graded with the use of protocol-
defined criteria. All other adverse events were 
graded with the use of the Table for Grading the 
Severity of Adult and Pediatric Adverse Events of 
the Division of AIDS.23
Secondary Outcomes
Key secondary maternal outcomes were adverse 
events of any cause of grade 3 or higher, hepato-
toxicity, death, and tuberculosis, assessed through 
week 48 after delivery. Hepatotoxicity was de-
fined as an elevation of grade 3 or higher in 
liver-enzyme levels (ALT, AST, or total bilirubin); 
an elevation of grade 2 or higher in total biliru-
bin and ALT levels; or an elevation of grade 2 or 
higher in ALT level with symptomatic clinical 
hepatitis. Key infant outcomes were adverse 
events of grade 3 or higher, tuberculosis, and 
death, assessed through week 48 after birth. The 
composite efficacy outcome was maternal tuber-
culosis, infant tuberculosis, maternal death, in-
fant death, or stillbirth or spontaneous abortion. 
Diagnosis of tuberculosis was categorized as 
probable or confirmed according to standardized 
criteria, and cases were reviewed by an indepen-
dent end-point review committee composed of 
five experts in maternal and pediatric tuberculo-
sis who were unaware of the trial-group assign-
ments.
The composite adverse pregnancy outcome, a 
key secondary outcome, was stillbirth (fetal death 
at 20 weeks of gestation or later) or spontaneous 
abortion (loss of pregnancy before 20 weeks of 
gestation), low birth weight (<2500 g) in an in-
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fant, preterm delivery (delivery before 37 weeks 
of gestation, with duration of gestation deter-
mined with the use of the Ballard examination 
when available or by obstetrical estimate), or 
major congenital anomalies in an infant (defined 
according to the Metropolitan Atlanta Congeni-
tal Defects Program of the Centers for Disease 
Control and Prevention24); adverse pregnancy 
outcomes were also assessed individually. The 
composite severe adverse pregnancy outcome 
was stillbirth or spontaneous abortion, very low 
birth weight (<1500 g) in an infant, very preterm 
delivery (delivery before 34 weeks of gestation), 
or major congenital anomalies in an infant.
Statistical Analysis
On the basis of previous studies of isoniazid 
preventive therapy in persons with HIV infec-
tion,10-12 we assumed that the incidence rate of 
the primary outcome would be 5 events per 100 
person-years in the deferred group. Noninferior-
ity of immediate isoniazid preventive therapy to 
deferred therapy with respect to the primary 
outcome would be shown if the upper boundary 
of the 95% confidence interval for the between-
group difference in the incidence rate was less 
than 5 events per 100 person-years. We calcu-
lated that 950 women (475 per group) would 
need to be enrolled to provide the trial with a 
power of at least 90% to show noninferiority of 
immediate therapy to deferred therapy, at a two-
sided alpha level of 0.05 (see the Supplementary 
Appendix).
All analyses were prespecified unless other-
wise noted. The primary analysis was performed 
on an intention-to-treat basis and included all 
women who underwent randomization, with data 
censored at the last trial visit. We performed a 
post hoc worst-case sensitivity analysis, in which 
participants who did not complete follow-up were 
considered as having had a primary outcome 
event, and a post hoc complete-case sensitivity 
analysis, which included only participants who 
had data available through week 48 after deliv-
ery. We also performed a per-protocol analysis, 
which included all eligible enrolled women who 
completed the trial regimen according to the 
protocol, all women in whom tuberculosis devel-
oped or who died during the treatment period, 
and all women who permanently discontinued 
the trial regimen because they met criteria for 
discontinuation as specified in the protocol. The 
absolute difference between groups in the rate 
of the primary outcome was calculated with the 
use of Mantel–Haenszel estimates, stratified ac-
cording to duration of gestation at trial entry; 
confidence intervals were calculated according 
to the method of Greenland and Robins,25 and 
the significance level was set at 5%, given that 
sequential monitoring with a Haybittle–Peto use 
function boundary for the alpha level was used 
for interim analyses.26 The percentage of partici-
pants with outcome events and the between-
group differences in the percentage, with 95% 
confidence intervals, were also computed. The 
efficacy outcomes of maternal tuberculosis and 
infant tuberculosis and the composite efficacy 
outcome were assessed in all mothers who un-
derwent randomization and their infants, except 
for mothers who underwent randomization but 
were later found to have had tuberculosis at the 
time of enrollment. The analysis of the compos-
ite efficacy outcome was stratified according to 
duration of gestation at trial entry.
Within-group incidence rates and 95% confi-
dence intervals for rate differences between 
groups were computed for secondary outcomes, 
except for the composite and individual preg-
nancy outcomes, which were compared with the 
use of Fisher’s exact test with mid-P adjust-
ment27; a two-sided P value of 0.05 or less was 
considered to indicate statistical significance. 
There was no adjustment for multiple testing in 
the analyses of secondary outcomes.
R esult s
Trial Population
From August 2014 through April 2016, a total of 
956 participants were enrolled; 477 women were 
assigned to the immediate group, and 479 to the 
deferred group (Fig. 1). The baseline characteris-
tics were well balanced between the two groups 
(Table 1). The median age was 29 years, 90.5% 
were black African, 33.6% had a duration of 
gestation of 14 weeks to less than 24 weeks, and 
30.0% had positive IGRA results for latent tuber-
culosis at enrollment. The median CD4 count 
was 493 cells per cubic millimeter, and all par-
ticipants except one were receiving highly active 
ART; in 85.1% of all participants, the regimen 
included efavirenz. A total of 171 women (17.9%) 
discontinued the trial prematurely: 6 women 
(0.6%) died (2 women in the immediate group 
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and 4 in the deferred group); 78 women (8.2%) 
withdrew consent (44 women in the immediate 
group and 34 in the deferred group); 1 woman 
(0.1%), in the deferred group, was not eligible; 
1 woman (0.1%), in the immediate group, enrolled 
in another study; and 85 women (8.9%) were lost 
to follow-up (41 women in the immediate group 
and 44 in the deferred group). The time to the 
last clinic visit was balanced between the two 
groups (Fig. S1 in the Supplementary Appendix). 
Data on adherence to isoniazid treatment were 
available for 466 participants in the immediate 
group and 413 participants in the deferred group. 
According to patient-reported adherence data, 
400 women (85.8%) in the immediate group and 
363 (87.9%) in the deferred group completed at 
least 90% of the treatment (P = 0.43 by Fisher’s 
exact test); according to assessment of pill count, 
408 of 463 women (88.1%) in the immediate 
group and 376 of 413 (91.0%) in the deferred 
group completed at least 90% of the treatment 
(P = 0.19 by Fisher’s exact test).
Primary Outcome
In the intention-to-treat population, a primary 
outcome event occurred in 72 women (15.1%) in 
the immediate group and in 73 (15.2%) in the 
deferred group (incidence rate, 15.03 and 14.93 
events per 100 person-years, respectively; rate 
difference, 0.10; 95% CI, −4.77 to 4.98) (Table 2). 
These results met the criterion for noninferiority 
of immediate treatment to deferred treatment. 
The results of the per-protocol analysis were 
consistent with these findings and also showed 
noninferiority. Treatment-related maternal ad-
verse events of grade 3 or higher and the num-
bers and percentages of participants who dis-
continued the trial regimen because of toxic 
effects are shown in Table 3. Additional data on 
incidence rates in the intention-to-treat and per-
protocol populations according to duration of 
gestation, reasons for discontinuation of the trial 
regimen, and estimated percentages of partici-
pants with primary and secondary outcome events 
are provided in Tables S1 through S3 in the Sup-
plementary Appendix.
The results of sensitivity analyses for missing 
data did not show noninferiority of immediate 
treatment to deferred treatment. In the worst-
case analysis, the between-group difference in 
the incidence rate was 1.45 events per 100 person-
years (95% confidence interval [CI], −5.49 to 8.4), 
and in the complete-case analysis, the between-
group difference in the incidence rate was 0.21 
events per 100 person-years (95% CI, −5.34 to 
5.75) (Table S4 in the Supplementary Appendix).
Secondary Maternal Safety Outcomes
Intention-to-treat analyses showed no significant 
differences in the incidence of adverse events of 
Figure 1. Enrollment, Randomization, and Analysis.
Participants were assigned to receive 28 weeks of isoniazid preventive ther‑
apy initiated either during pregnancy (immediate group) or at 12 weeks after 
delivery (deferred group). Participants were excluded from the per‑protocol 
analysis for one or more of the following reasons: they withdrew consent, 
they were lost to follow‑up, they did not complete the trial regimen according 
to the protocol, or they had been found after randomization to be ineligible.
956 Underwent randomization
1361 Women were assessed for eligibility
477 Were assigned to the immediate
group
475 Received isoniazid or placebo
2 Did not receive isoniazid or
placebo
479 Were assigned to the deferred
group
479 Received isoniazid or placebo
477 Were included in the intention-
to-treat analysis
101 Were excluded from the per-
protocol analysis
376 Were included in the per-protocol
analysis
479 Were included in the intention-
to-treat analysis
91 Were excluded from the per-
protocol analysis
388 Were included in the per-protocol
analysis
118 Did not complete the trial
regimen
16 Had toxic effects
2 Had tuberculosis diagnosis
9 Became pregnant
76 Discontinued the trial while
receiving the trial regimen
15 Had other reason
88 Did not complete the trial
44 Withdrew consent
41 Were lost to follow-up
2 Died
1 Had other reason
120 Did not complete the trial
regimen
28 Had toxic effects
1 Had tuberculosis diagnosis
7 Became pregnant
65 Discontinued the trial while
receiving the trial regimen
19 Had other reason
83 Did not complete the trial
34 Withdrew consent
44 Were lost to follow-up
4 Died
1 Had other reason
405 Were excluded
330 Were not eligible
1 Died
32 Declined to participate
13 Did not return to the clinic
29 Had other reason
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Median age (IQR) — yr 29 (25–33) 29 (24–33)
Ethnic group — no. (%)†
Black African 436 (91.4) 429 (89.6)
Black, of African origin  8 (1.7) 15 (3.1)
Indian or South Asian 17 (3.6) 15 (3.1)
Thai 10 (2.1) 12 (2.5)
Other Asian  5 (1.0)  8 (1.7)
Mixed, of predominantly African ancestry  1 (0.2) 0
Country — no. (%)
Botswana  60 (12.6)  60 (12.5)
Haiti  8 (1.7) 15 (3.1)
India 17 (3.6) 16 (3.3)
South Africa  91 (19.1)  91 (19.0)
Tanzania 41 (8.6) 39 (8.1)
Thailand 15 (3.1) 18 (3.8)
Uganda  83 (17.4)  83 (17.3)
Zimbabwe 162 (34.0) 157 (32.8)
Gestation — no. (%)
14 to <24 wk 161 (33.8) 160 (33.4)
24 to ≤34 wk 316 (66.2) 319 (66.6)
Median body‑mass index (IQR)‡ 26 (23–30) 26 (23–30)
Median CD4 count (IQR) — cells/mm3 491 (351–670) 496 (355–669)
HIV RNA level below the lower limit of quantification 
— no./total no. (%)
303/476 (63.7) 299/478 (62.6)
WHO clinical stage 1 — no. (%)§ 426 (89.3) 419 (87.5)
Receipt of highly active antiretroviral therapy at entry 
— no. (%)
476 (99.8)  479 (100.0)
Efavirenz–tenofovir–emtricitabine or lamivudine 401 (84.1) 401 (83.7)
Efavirenz–zidovudine–lamivudine  3 (0.6)  8 (1.7)
Nevirapine–zidovudine or tenofovir–emtricitabine 
or lamivudine
 59 (12.4)  61 (12.7)
Lopinavir or atazanavir–ritonavir with tenofovir  
or zidovudine–emtricitabine or lamivudine
13 (2.7)  9 (1.9)
Receipt of efavirenz only at entry — no. (%)  1 (0.2) 0
Positive IGRA status — no./total no. (%) 139/470 (29.6) 144/472 (30.5)
Positive test for hepatitis B surface antigen  
— no./total no. (%)
15/476 (3.2) 18/479 (3.8)
Positive serologic test for hepatitis C — no./total no. (%) 5/449 (1.1) 4/445 (0.9)
*  Percentages may not total 100 because of rounding. HIV denotes human immunodeficiency virus, IGRA interferon 
gamma release assay, and IQR interquartile range.
†  Ethnic group was reported by the participants and categorized by trained staff according to categories defined by the 
Division of AIDS of the National Institute of Allergy and Infectious Diseases.
‡  The body‑mass index is the weight in kilograms divided by the square of the height in meters.
§  World Health Organization (WHO) stage 1 indicates asymptomatic HIV infection.
Table 1. Maternal Characteristics at Baseline.*
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any cause (treatment-related or not) of grade 3 or 
higher (Tables 2 through 4). The incidence rate 
of any grade 3 or 4 adverse event related to isonia-
zid or placebo was 34.95 per 100 person-years in 
the immediate group and 31.26 per 100 person-
years in the deferred group (rate difference, 3.69; 
95% CI, −4.07 to 11.45). The incidence rate of 
hepatotoxicity was 5.80 and 6.69 per 100 person-
years, respectively (rate difference, −0.89; 95% 
CI, −3.98 to 2.19).
Six women died — 2 women in the immedi-
ate group and 4 in the deferred group (incidence 




incidence rate per  
100 person-yr no./total no. (%)
incidence rate per  
100 person-yr
Primary outcome†
Intention‑to‑treat population 72/477 (15.1) 15.03 73/479 (15.2) 14.93 0.10 (−4.77 to 4.98)
Per‑protocol population 64/376 (17.0) 16.00 69/388 (17.8) 16.71 −0.71 (−6.27 to 4.85)
Secondary maternal outcomes
Any grade 3 or 4 adverse event 144/477 (30.2) 34.95 136/479 (28.4) 31.26 3.69 (−4.07 to 11.45)
Hepatotoxicity‡ 29/477 (6.1) 5.80 34/479 (7.1) 6.69 −0.89 (−3.98 to 2.19)
Peripheral neuropathy 1/477 (0.2) 0.19 0/479 (0.0) 0.00 0.19 (−0.19 to 0.57)
Death 2/477 (0.4) 0.40 4/479 (0.8) 0.78 −0.39 (−1.33 to 0.56)
Death due to hepatitis after  
receiving isoniazid§
1/477 (0.2) 0.20 1/479 (0.2) 0.20 0.00 (−0.54 to 0.55)
Permanent discontinuation of trial  
regimen because of toxic  
effects§
16/477 (3.4) 3.16 28/479 (5.8) 5.48 −2.32 (−4.88 to 0.23)
Tuberculosis¶ 3/477 (0.6) 0.60 3/478 (0.6) 0.59 0.01 (−0.94 to 0.96)
Secondary infant outcomes
Any grade 3 or 4 adverse event 191/445 (42.9) 70.74 192/464 (41.4) 65.75 4.99 (−8.69 to 18.67)
HIV infection 3/439 (0.7) 0.79 7/458 (1.5) 1.75 −0.96 (−2.54 to 0.61)
Infant death: 0–48 wk after birth 11/445 (2.5) 2.99 17/464 (3.7) 4.42 −1.43 (−4.17 to 1.32)
Neonatal death: 0–7 days after birth‖ 4/445 (0.9) — 5/464 (1.1) — —
Tuberculosis** 0/445 (0.0) 0.54 1/464 (0.2) 0.52 0.02 (−1.02 to 1.07)
*  All analyses were performed on an intention‑to‑treat basis unless otherwise specified. Incidence rates were used to summarize the outcomes, 
given that the follow‑up period of observation was expected to vary from 48 weeks to 74 weeks, depending on the duration of gestation  
at entry. The noninferiority margin was an upper boundary of the 95% confidence interval for the difference in the rate of the primary out‑
come between the two groups of less than 5 events per 100 person‑years.
†  The primary safety outcome was a maternal adverse event of grade 3 or higher that was possibly, probably, or definitely related to isoniazid  
or placebo (as adjudicated by an independent end‑point review committee, whose members were unaware of the trial‑group assignments) 
or permanent discontinuation of the trial regimen because of toxic effects, whichever occurred earlier. The intention‑to‑treat population in‑
cluded all women who underwent randomization. The per‑protocol population included all eligible enrolled women who completed the trial 
regimen according to the protocol, who died during the treatment period, and who permanently discontinued the trial regimen because 
they met criteria for discontinuation as specified in the protocol, and all women in whom tuberculosis developed.
‡  Hepatotoxicity was defined as an elevation of grade 3 or higher in liver‑enzyme levels (alanine aminotransferase [ALT], aspartate amino‑
transferase, or total bilirubin); a grade 2 or higher elevation in total bilirubin and ALT levels; or a grade 2 or higher elevation in ALT level 
with symptomatic clinical hepatitis.
§  The analysis of this outcome was a post hoc analysis. Additional details are provided in Table S5 in the Supplementary Appendix.
¶  Of the six cases of tuberculosis adjudicated by the independent end‑point review committee, four were confirmed cases of pulmonary 
 tuberculosis and two were probable cases of pulmonary tuberculosis. Three cases were in women who had positive IGRA status at entry, 
one case was in a woman with indeterminate status at entry, and one case was in a woman whose IGRA status changed from negative to 
positive before tuberculosis diagnosis (Table S6 in the Supplementary Appendix).
‖  Incidence rates are not reported for this category because of the short follow‑up time.
**  The calculation of the incidence rates in this category includes deaths from unknown causes (two in the immediate group and one in the 
deferred group).
Table 2. Primary Safety Outcome and Secondary Maternal and Infant Outcomes through Week 48 after Delivery.*
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rate, 0.40 and 0.78 per 100 person-years, respec-
tively; rate difference, −0.39; 95% CI, −1.33 to 
0.56) (Table 2, and Table S5 in the Supplemen-
tary Appendix). The primary cause of death in 
4 of the women (1 in the immediate group and 
3 in the deferred group) was liver failure, and all 
the deaths occurred during the postpartum peri-
od; 2 women had received isoniazid (1 woman in 
each group), and all 4 were receiving efavirenz–
tenofovir–emtricitabine at the time of death.
There were no noted imbalances between the 
groups in the prevalence of peripheral neuropa-
thy or hepatotoxicity (Table 2 and Fig. 2A). 
Symptomatic hepatitis developed in 11 women 
(1.2%) — 3 women in the immediate group and 
8 in the deferred group. All cases of symptom-
atic hepatitis occurred during the postpartum 
period; at the time of the event, 4 women were 
receiving isoniazid, and 4 women had discontin-
ued isoniazid at 2.4 weeks, 4.9 weeks, 14.7 weeks, 
and 15.7 weeks before symptom onset. A total of 
63 women had elevations in liver-enzyme levels 
of grade 3 or higher or symptomatic hepatitis (or 
both); at the time of the first event, 32 women 
were receiving isoniazid in addition to efavirenz-
based ART, 22 were receiving efavirenz-based 
ART only, and 6 were receiving isoniazid in ad-
dition to non–efavirenz-based ART.
Adverse Pregnancy Outcomes and Outcomes 
in Infants
There were 926 deliveries. A greater percentage 
of women in the immediate group than in the 








number of participants (percent)
Any treatment‑related grade ≥3 adverse event 70 (15) 70 (15) 140 (15)
Grade ≥3 abnormal laboratory findings 27 (6) 36 (8) 63 (7)
Abnormal laboratory chemical values 26 (5) 34 (7) 60 (6)
Elevated liver‑enzyme levels 26 (5) 33 (7) 59 (6)
Abnormal hematologic values 1 (<1) 3 (1) 4 (<1)
Grade ≥3 clinical adverse event 50 (10) 41 (9) 91 (10)
Gastrointestinal event 2 (<1) 1 (<1) 3 (<1)
Hepatitis 4 (1) 5 (1) 9 (1)
Nervous system disorder 1 (<1) 2 (<1) 3 (<1)
Peripheral neuropathy 1 (<1) 0 1 (<1)
Event related to pregnancy, the puerperium, or 
the perinatal period
15 (3) 13 (3) 28 (3)
Eclampsia or preeclampsia 5 (1) 3 (1) 8 (1)
Gestational hypertension 1 (<1) 2 (<1) 3 (<1)
Hemorrhage 1 (<1) 1 (<1) 2 (<1)
Stillbirth or spontaneous abortion† 6 (1) 2 (<1) 8 (1)
Weight loss‡ 30 (6) 24 (5) 54 (6)
Other clinical adverse event 5 (1) 2 (<1) 7 (1)
Permanent discontinuation of trial regimen because 
of toxic effects, but no treatment‑related 
grade ≥3 adverse events
2 (<1) 3 (<1) 5 (<1)
*  Treatment‑related adverse events were events that were possibly, probably, or definitely related to isoniazid or placebo.
†  Stillbirth was defined as fetal death at 20 weeks of gestation or later. Spontaneous abortion was defined as loss of preg‑
nancy before 20 weeks of gestation.
‡  Weight loss was defined as unintentional loss of at least 10% of body weight (see the Supplementary Appendix).
Table 3. Treatment-Related Maternal Adverse Events of Grade 3 or Higher and Discontinuation of the Trial Regimen 
Because of Toxic Effects.*
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nancy outcome event (23.6% vs. 17.0%; differ-
ence, 6.7 percentage points; 95% CI, 0.8 to 11.9; 
P = 0.01) (Fig. 2B). There was a higher frequency 
of each of the individual adverse pregnancy out-
comes in the immediate group than in the de-
ferred group, but none of the between-group 
differences were significant. With respect to the 
composite severe adverse pregnancy outcome, 
no significant difference was observed between 
the immediate group and the deferred group 
(6.3% vs. 4.6%; difference, 1.7 percentage points; 
95% CI, −1.3 to 4.8; P = 0.27). The results of a 
post hoc analysis of adverse pregnancy outcomes 
according to duration of gestation are provided 
in Figure S3 in the Supplementary Appendix; the 
analysis was not adjusted for multiple compari-
sons. Among the 909 infants born alive, no im-
balances between groups were noted in adverse 
events of grade 3 or higher, HIV infection, or 
death assessed through week 48 after birth 
(Table 2).
Tuberculosis and Composite Efficacy 
Analyses
One woman with confirmed tuberculosis at entry 
was excluded from the analysis of efficacy out-
comes. Tuberculosis developed in 6 women (3 in 
each group), and all cases occurred during the 
postpartum period (Table 2, and Table S6 in the 
Supplementary Appendix). The incidence rate of 
maternal tuberculosis was 0.60 and 0.59 per 100 
person-years, respectively (rate difference, 0.01; 
95% CI, −0.94 to 0.96). Four cases were con-
firmed (one was a case of monoresistant [i.e., 
isoniazid-resistant] tuberculosis), and two cases 
were probable. There were no cases of tubercu-
losis in infants in the immediate group, and a 








number of participants (percent)
Any grade ≥3 adverse event 144 (30) 136 (28) 280 (29)
Any grade ≥3 serious adverse event* 69 (14) 66 (14) 135 (14)
Grade ≥3 abnormal laboratory findings 63 (13) 59 (12) 122 (13)
Abnormal laboratory chemical values 34 (7) 40 (8) 74 (8)
Elevated liver‑enzyme levels 29 (6) 34 (7) 63 (7)
Abnormal hematologic values 35 (7) 24 (5) 59 (6)
Grade ≥3 clinical adverse event 106 (22) 98 (20) 204 (21)
Gastrointestinal event 8 (2) 7 (1) 15 (2)
Hepatitis 5 (1) 6 (1) 11 (1)
Infection 17 (4) 14 (3) 31 (3)
Nervous system disorder 4 (1) 5 (1) 9 (1)
Peripheral neuropathy 1 (<1) 0 1 (<1)
Event related to pregnancy, the puerperium, 
or the perinatal period
41 (9) 39 (8) 80 (8)
Eclampsia or preeclampsia 8 (2) 4 (1) 12 (1)
Gestational hypertension 4 (1) 5 (1) 9 (1)
Hemorrhage 5 (1) 7 (1) 12 (1)
Stillbirth or spontaneous abortion† 18 (4) 9 (2) 27 (3)
Weight loss 31 (6) 27 (6) 58 (6)
Other clinical adverse event 36 (8) 31 (6) 67 (7)
*  A serious adverse event was defined as any adverse event that resulted in death, a life‑threatening condition, inpatient 
hospitalization, prolongation of an existing hospitalization, or a persistent or clinically significant disability or incapacity.
†  One event in the immediate group was from a subsequent pregnancy.
Table 4. Maternal Adverse Events of Grade 3 or Higher Regardless of Relatedness to the Trial Regimen.
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Figure 2. Hepatotoxicity and Adverse Pregnancy Outcomes.
Hepatotoxicity (Panel A) was defined as a grade 3 or higher elevation in liver‑enzyme levels (alanine aminotransferase [ALT], aspartate 
aminotransferase, or total bilirubin), a grade 2 or higher elevation in total bilirubin and ALT levels, or a grade 2 or higher elevation in ALT 
level with symptomatic clinical hepatitis. Grading of hepatotoxicity was determined on the basis of criteria specified in the protocol. The 
composite adverse pregnancy outcome (Panel B) was stillbirth (fetal death at 20 weeks of gestation or later) or spontaneous abortion 
(loss of pregnancy before 20 weeks of gestation), low birth weight (<2500 g) in an infant, preterm delivery (delivery before 37 weeks of 
gestation, with duration of gestation determined with the use of the Ballard examination when available or by obstetrical estimate), or 
major congenital anomalies in an infant (defined according to the criteria of the Metropolitan Atlanta Congenital Defects Program of the 
Centers for Disease Control and Prevention24). The composite severe adverse pregnancy outcome was stillbirth or spontaneous abortion, 
very low birth weight (<1500 g) in an infant, very preterm delivery (delivery before 34 weeks of gestation), or major congenital anomalies 
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infant in the deferred group at 12 months of 
age. In an analysis stratified according to dura-
tion of gestation at trial entry, there were no 
between-group differences in the time to the 
composite efficacy outcome (Fig. S2B in the 
Supplementary Appendix). Attempts were made 
to contact the 85 women who were lost to fol-
low-up; we were able to ascertain vital status for 
74 of these women (87.1%). No maternal deaths, 
hospitalizations, or tuberculosis cases were re-
ported.
Discussion
Isoniazid in addition to ART is strongly recom-
mended for the prevention of tuberculosis in pa-
tients with HIV infection.14 On the basis of data 
from nonpregnant adults and the absence of 
harm observed in small studies of isoniazid pre-
ventive therapy in pregnancy,28-30 the WHO rec-
ommends isoniazid preventive therapy and ART 
during pregnancy,14 but it has acknowledged the 
need for pregnancy-specific data.14 This trial 
showed that isoniazid preventive therapy initi-
ated during pregnancy was noninferior to initia-
tion at 3 months after delivery with respect to 
maternal adverse events, and there was a low 
incidence of tuberculosis in both groups. How-
ever, with careful clinical monitoring and moni-
toring of liver function, we observed a higher 
incidence of maternal treatment-related serious 
adverse events during the postpartum period than 
expected in both the immediate group and the 
deferred group. We also observed a higher inci-
dence of adverse pregnancy outcomes in the 
immediate group than in the deferred group 
when analyzed a priori as a composite outcome. 
No other differences in secondary maternal or 
infant outcomes were observed between groups.
Risk factors for hepatotoxicity (including drug-
induced hepatotoxicity) include female sex, preg-
nancy, delivery within the previous 3 months, 
and obesity.20,31 Retrospective data from the 1980s 
have suggested a higher risk of toxic effects re-
lated to isoniazid treatment during pregnancy 
and the postpartum period, and this formed the 
basis of the recommendation of the Centers for 
Disease Control and Prevention to defer isonia-
zid preventive therapy to the postpartum period 
in women without HIV infection.18,32-34 However, 
more recent small studies involving women who 
became pregnant while receiving isoniazid pre-
ventive therapy or who started receiving isonia-
zid preventive therapy during pregnancy did not 
show increased adverse events.28-30 We reviewed 
seven trials of isoniazid preventive therapy in 
nonpregnant adults in which liver function was 
monitored, albeit with variable algorithms and 
with variable proportions of participants who 
were receiving ART (Table S7 in the Supplemen-
tary Appendix).10-13,35-37 Whereas in our trial in 
pregnant women, 6.6% of participants had hepa-
totoxicity of grade 3 or higher (including four 
events of symptomatic hepatitis and two deaths 
[0.2%] due to liver failure) while receiving iso-
niazid, studies in nonpregnant women showed 
lower percentages of participants with hepato-
toxicity of grade 3 or higher, ranging from 1.1 to 
2.9% in five trials totaling 8084 participants and 
from 4.0 to 5.5% in smaller trials involving less 
than 400 participants. Furthermore, in five trials, 
no deaths or a small number of deaths due to 
liver failure were reported in groups that re-
ceived isoniazid (0 to 0.05%)10,12,13,35,36,38; in two 
trials, deaths were reported, but they were of 
unknown cause, and the relatedness to the trial 
drug was unclear.11,37
In the current trial, the majority of elevations 
in liver-enzyme levels of grade 3 or higher and 
all cases of symptomatic hepatitis and death oc-
curred during the postpartum period; this high-
lights the importance of postpartum monitoring 
and follow-up. Some of these events were not 
considered to be associated with isoniazid, and 
all these events occurred in participants who 
were receiving efavirenz-based ART. No other 
cause of maternal death from liver failure (e.g., 
hepatitis A, hepatitis B, hepatitis C, or acetamino-
phen use) could be identified. It is possible that 
efavirenz — the first-line ART in 85% of our 
participants and a drug that has been associated 
with hepatotoxicity of grade 3 or higher or drug 
discontinuation in 2.3% of patients39 and fulmi-
nant hepatic failure in women40 — contributed 
to liver failure and death. An interaction between 
efavirenz and isoniazid may be a contributing 
factor, because isoniazid appears to inhibit an 
accessory pathway of efavirenz metabolism, which 
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results in higher efavirenz levels, particularly in 
women who have slow metabolizing genotypes 
for both drugs (e.g., N-acetyltransferase 2 slow 
acetylator and CYP2B6 TT).41
The higher incidence of the composite ad-
verse pregnancy outcome among women in the 
immediate group than in the deferred group was 
a new finding. When examined separately, there 
were no significant between-group differences 
in any of the adverse pregnancy outcomes, al-
though the frequencies of stillbirth or spontane-
ous abortion and low birth weight in an infant 
were numerically higher in the immediate group 
than in the deferred group. Studies in animals 
have shown that animals that receive at least 
twice the therapeutic dose of isoniazid have 
smaller litter sizes and offspring with a lower 
birth weight than those in comparison groups.42-44 
Although the adverse pregnancy outcomes in this 
trial could be due to chance, given the large 
number of secondary outcomes that were ana-
lyzed, our results highlight a safety concern that 
warrants further examination.
This trial had limitations. We excluded women 
who were in the first trimester of pregnancy, 
and we did not evaluate the effect of isoniazid 
on organogenesis. We also excluded women 
with recent tuberculosis exposure — a group in 
which there is a higher risk of tuberculosis. Our 
noninferiority margin was just reached, and the 
results of the primary analysis were not robust 
to assumptions regarding missing data. Most 
participants were receiving efavirenz, and other 
antiretroviral agents may have a different risk–
benefit profile. We observed low rates of tuber-
culosis, most likely because all participants 
received ART and isoniazid, because we used 
systematic baseline screening for tuberculosis, 
and because not all participants had latent tuber-
culosis infection (only 30% had latent infection 
at entry). Finally, the trial included monthly 
monitoring of liver-enzyme levels and other safe-
ty measures, rather than just monitoring of symp-
toms, which is the standard of care in current 
HIV and tuberculosis programs because of re-
source constraints as well as controversy regard-
ing the clinical importance of asymptomatic ele-
vated liver-enzyme levels.31 It is possible that we 
misclassified transient hepatic adaptation (a non-
progressive injury to hepatocyte cell structures) 
as liver injury because of our more intensive 
monitoring of laboratory values. Conversely, our 
frequent monitoring and management of elevat-
ed liver-enzyme levels may have averted severe 
hepatotoxicity.
The combination of isoniazid preventive ther-
apy and ART is effective in reducing the risk of 
HIV-associated tuberculosis.11,14,36 In women with 
HIV infection who were receiving ART, the ini-
tiation of isoniazid preventive therapy during 
pregnancy was noninferior to initiation during 
the postpartum period with respect to maternal 
treatment-related adverse events. However, our 
finding of a greater incidence of adverse preg-
nancy outcomes in the immediate group than in 
the deferred group without any additional benefit 
with respect to the risk of tuberculosis or maternal 
or infant death is a cause for concern. Shorter-
course regimens (such as isoniazid and rifapentine 
administered for 1 month or 3 months10,12,13,35,36,38) 
initiated during pregnancy may have different 
risk–benefit profiles, and further study is war-
ranted. Our trial highlights the need to include 
pregnant women in clinical trials to inform 
global health policy.8,9
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